ChitogenX Inc. (CHGX.CN)
CAD 0.01
(0.0%)
CAD 0.01
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.83 Million CAD | -39.9% |
| 2022 | 4.7 Million CAD | 44.58% |
| 2021 | 3.25 Million CAD | 11.16% |
| 2020 | 2.93 Million CAD | 34.22% |
| 2019 | 2.18 Million CAD | -5.29% |
| 2018 | 2.3 Million CAD | 28.96% |
| 2017 | 1.78 Million CAD | 68.46% |
| 2016 | 1.06 Million CAD | 60.2% |
| 2015 | 662.34 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 33 Thousand CAD | -95.5% |
| 2024 Q2 | 216 Thousand CAD | 554.55% |
| 2023 Q3 | 357 Thousand CAD | -38.87% |
| 2023 Q1 | 1.05 Million CAD | -8.95% |
| 2023 Q2 | 584 Thousand CAD | -44.8% |
| 2023 Q4 | 734 Thousand CAD | 105.6% |
| 2023 FY | 2.78 Million CAD | -40.79% |
| 2022 Q2 | 1.09 Million CAD | -14.31% |
| 2022 FY | 4.7 Million CAD | 44.58% |
| 2022 Q4 | 1.16 Million CAD | -1.94% |
| 2022 Q3 | 1.18 Million CAD | 8.72% |
| 2022 Q1 | 1.27 Million CAD | 60.81% |
| 2021 Q4 | 791 Thousand CAD | -20.18% |
| 2021 Q1 | 903 Thousand CAD | -7.29% |
| 2021 Q2 | 572 Thousand CAD | -36.66% |
| 2021 Q3 | 991 Thousand CAD | 73.25% |
| 2021 FY | 3.25 Million CAD | 11.16% |
| 2020 Q4 | 974 Thousand CAD | 53.63% |
| 2020 FY | 2.93 Million CAD | 34.22% |
| 2020 Q3 | 634 Thousand CAD | 47.44% |
| 2020 Q1 | 892 Thousand CAD | 154.86% |
| 2020 Q2 | 430 Thousand CAD | -51.79% |
| 2019 FY | 2.18 Million CAD | -5.29% |
| 2019 Q4 | 350 Thousand CAD | -45.14% |
| 2019 Q3 | 638 Thousand CAD | 6.51% |
| 2019 Q2 | 599 Thousand CAD | 14.75% |
| 2019 Q1 | 522 Thousand CAD | -25.83% |
| 2018 Q2 | 445.13 Thousand CAD | 9.32% |
| 2018 Q1 | 407.2 Thousand CAD | -29.27% |
| 2018 Q3 | 748.89 Thousand CAD | 68.24% |
| 2018 Q4 | 703.81 Thousand CAD | -6.02% |
| 2018 FY | 2.3 Million CAD | 28.96% |
| 2017 FY | 1.78 Million CAD | 68.46% |
| 2017 Q1 | 175.38 Thousand CAD | 7.78% |
| 2017 Q2 | 382.84 Thousand CAD | 118.29% |
| 2017 Q3 | 596.09 Thousand CAD | 55.7% |
| 2017 Q4 | 575.68 Thousand CAD | -3.42% |
| 2016 Q2 | 348.87 Thousand CAD | 29.1% |
| 2016 FY | 1.06 Million CAD | 60.2% |
| 2016 Q4 | 162.71 Thousand CAD | -41.72% |
| 2016 Q1 | 270.24 Thousand CAD | -33.36% |
| 2016 Q3 | 279.21 Thousand CAD | -19.97% |
| 2015 Q2 | 53.58 Thousand CAD | 46.68% |
| 2015 FY | 662.34 Thousand CAD | 0.0% |
| 2015 Q4 | 405.54 Thousand CAD | 143.3% |
| 2015 Q1 | 36.53 Thousand CAD | 0.0% |
| 2015 Q3 | 166.68 Thousand CAD | 211.07% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | 5.19 Million CAD | 45.489% |
| Asep Medical Holdings Inc | 7.74 Million CAD | 63.448% |
| BetterLife Pharma Inc. | 3.24 Million CAD | 12.661% |
| BioVaxys Technology Corp. | 2.4 Million CAD | -17.789% |
| Rapid Dose Therapeutics Corp. | 4.2 Million CAD | 32.754% |
| Defence Therapeutics Inc. | 12.65 Million CAD | 77.639% |
| Entheon Biomedical Corp. | 564.31 Thousand CAD | -401.493% |
| Gemina Laboratories Ltd. | 5.08 Million CAD | 44.356% |
| Glow Lifetech Corp. | 25.71 Thousand CAD | -10905.25% |
| Lexston Life Sciences Corp. | 674.71 Thousand CAD | -319.434% |
| Pharmala Biotech Holdings Inc. | 1.21 Million CAD | -132.53% |
| Doseology Sciences Inc. | 72.08 Thousand CAD | -3825.812% |
| MYND Life Sciences Inc. | 1.47 Million CAD | -91.892% |
| Nova Mentis Life Science Corp. | 1.2 Million CAD | -135.382% |
| PharmaTher Holdings Ltd. | 3.04 Million CAD | 7.033% |
| PreveCeutical Medical Inc. | 963.12 Thousand CAD | -193.835% |
| Telescope Innovations Corp. | 6.35 Million CAD | 55.449% |